Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2025-03-03 Sale |
2025-03-04 8:06 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
15,103 | $42.1 | $635,836 | 118,101 (Direct) |
View |
| 2024-03-01 Sale |
2024-03-05 8:08 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
4,768 | $53.76 | $256,328 | 101,363 (Direct) |
View |
| 2023-09-05 Sale |
2023-09-06 5:51 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
6,000 | $37.96 | $227,760 | 51,281 (Direct) |
View |
| 2023-06-19 Sale |
2023-06-21 6:17 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
305 | $48.2 | $14,701 | 57,281 (Direct) |
View |
| 2023-03-01 Sale |
2023-03-03 7:51 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
3,664 | $45.25 | $165,796 | 96,744 (Direct) |
View |
| 2022-06-19 Sale |
2022-06-22 7:27 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
295 | $54.78 | $16,160 | 36,160 (Direct) |
View |
| 2022-03-01 Sale |
2022-03-03 6:11 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
2,713 | $66.62 | $180,740 | 61,217 (Direct) |
View |
| 2021-10-14 Sale |
2021-10-18 6:58 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
303 | $81.14 | $24,585 | 25,030 (Direct) |
View |
| 2021-07-06 Sale |
2021-07-08 11:56 am |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
375 | $91.53 | $34,324 | 25,333 (Direct) |
View |
| 2021-06-19 Sale |
2021-06-23 5:55 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
1,009 | $94.82 | $95,670 | 25,708 (Direct) |
View |
| 2021-05-06 Sale |
2021-05-10 6:10 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
700 | $113.67 | $79,572 | 26,717 (Direct) |
View |
| 2021-04-20 Sale |
2021-04-21 8:07 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
396 | $104.28 | $41,295 | 27,417 (Direct) |
View |
| 2021-03-01 Sale |
2021-03-03 8:42 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
3,177 | $138.17 | $438,959 | 38,813 (Direct) |
View |
| 2020-06-03 Sale |
2021-02-03 8:04 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
2,516 | $74.69 | $187,920 | 20,854 (Direct) |
View |
| 2020-10-14 Sale |
2020-10-16 7:20 pm |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
220 | $88 | $19,360 | 23,370 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-03-25 Option Award |
2025-03-26 7:37 pm |
N/A 2035-03-25 |
Rezolute Inc. | RZLT | Harris Erik Director |
60,000 | $0 | 60,000 (Direct) |
View |
| 2025-03-01 Option Award |
2025-03-04 8:06 pm |
N/A 2035-03-01 |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
65,502 | $0 | 118,101 (Direct) |
View |
| 2024-10-03 Option Award |
2024-10-07 4:37 pm |
N/A 2034-10-02 |
Inozyme Pharma Inc. | INZY | Harris Erik Director |
56,000 | $0 | 56,000 (Direct) |
View |
| 2024-05-31 Option Award |
2024-06-04 6:27 pm |
N/A 2034-05-31 |
Denali Therapeutics Inc. | DNLI | Harris Erik Director |
23,868 | $0 | 34,953 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-05 8:08 pm |
N/A 2034-03-01 |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
54,557 | $0 | 101,363 (Direct) |
View |
| 2023-06-01 Option Award |
2023-06-05 6:02 pm |
N/A 2033-06-01 |
Denali Therapeutics Inc. | DNLI | Harris Erik Director |
16,865 | $0 | 23,734 (Direct) |
View |
| 2023-03-01 Option Award |
2023-03-03 7:51 pm |
N/A 2033-03-01 |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
64,063 | $0 | 96,744 (Direct) |
View |
| 2022-03-01 Option Award |
2022-03-03 6:11 pm |
N/A 2032-03-01 |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
38,900 | $0 | 61,217 (Direct) |
View |
| 2022-02-03 Option Award |
2022-02-07 6:54 pm |
N/A 2032-02-03 |
Denali Therapeutics Inc. | DNLI | Harris Erik Director |
27,476 | $0 | 27,476 (Direct) |
View |
| 2021-03-01 Option Award |
2021-03-03 8:42 pm |
N/A 2031-03-01 |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
21,136 | $0 | 38,813 (Direct) |
View |
| 2020-07-06 Tax Withholding |
2020-07-08 12:29 pm |
N/A N/A |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
260 | $86.75 | 23,590 (Direct) |
View |
| 2020-06-19 Tax Withholding |
2020-06-22 1:47 pm |
N/A N/A |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
303 | $78.22 | 23,850 (Direct) |
View |
| 2020-05-06 Tax Withholding |
2020-05-08 8:11 pm |
N/A N/A |
Ultragenyx Pharmaceutical Inc. | RARE | Harris Erik EVP & Chief Commercial Officer |
209 | $66.26 | 24,153 (Direct) |
View |